A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Aravive S6 (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors Aravive Biologics
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.
- 29 Jan 2018 According to a WuXi Biologics media release, the company has successfully filed an IND application and expects to begin this trial in the first quarter of 2018.
- 23 Jan 2018 New trial record